Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pain. -- The two major causes of progression in the SPARC trial - radiologic progression and pain progression - were each associated with a 36% reduction in relative risk of disease progression.

MARTINSRIED/MUNICH, Germany, June 04, 2007 /PRNewswire-FirstCall/ -- Princeton, N.J., and Boulder, CO -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. A New Drug Application (NDA) for satraplatin is currently under priority review by the U.S. Food and Drug Administration (FDA).

"Today hormone-refractory prostate cancer patients whose chemotherapy has failed have no approved treatment options. The data I have presented today from the SPARC trial show that satraplatin lowers the risk of disease progression by 33% compared to control. The data are consistent across numerous pre-defined subsets, including patients previously treated with Taxotere," said Cora Sternberg, M.D., FACP, Chief of the Department of Medical Oncology at the San Camillo and Forlanini Hospitals, Rome, Italy and one of the principal investigators of the SPARC registrational trial. "I believe these efficacy results, together with satraplatin's manageable side e
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:12/22/2014)... Tenn. , Dec. 22, 2014   TRU-D ... automated, no-touch UV disinfection robot, announced today that the ... Schedule contract through November 2019.   This ... rapidly engage all levels of government purchasers, including Department ... as well as Homeland Security contacts purchasing solutions for ...
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah ... brief providing a summary of the 2015 marketplace ... enrollment trends.  According to a ... Planning and Evaluation, Department of Health and Human ... enrolled in individual medical plans through the Marketplace ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... Meeting , , ATLANTA, Dec. ... the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets ... additional dosing schedules. The data were among five studies that ... Epilepsy Society (AES) in Seattle. , ...
... Millennium: The Takeda Oncology Company today reported updated ... from the large, international Phase III VISTA(1) trial ... untreated multiple myeloma given VELCADE, melphalan and prednisone ... all patient sub-groups, including those with poor prognostic ...
Cached Medicine Technology:New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 2New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 3New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 4New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 5New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 6Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... June 2011 The Reed Elsevier Environmental Challenge aims ... and sustainable water supply for communities where it is ... $50,000 first prize, announced today, is Tagore-SenGupta Foundation. Their ... in remote villages and schools in Cambodia where arsenic ...
... highlights that while the risk of post-traumatic stress disorder (PTSD) ... migraine irrespective of sex, the risk is greater in male ... Headache: The Journal of Head and Face Pain , ... In this paper, lead author B. Lee Peterlin ...
... range of new "apps" and other technologies harnessing health ... demonstrated at the Health Data Initiative Forum, hosted by ... and Human Services, on Thursday, June 9. IT ... gather at the event hosted by the Institute of ...
... bona fide media presenting official press credentials , Media ... & IT support, English, Swedish, Spanish, German, and French ... is English] News briefings will be held:, ... CEST Monday 4 July (English), 14.00 hrs CEST Monday ...
... to suffer surgical site infections (SSIs) if the operating theatre ... of BJS, the British Journal of Surgery . ... surgery, exploring demographic parameters, the duration of the operation and ... per cent) developed SSIs and the only variable was the ...
... Asian non-small cell lung cancer (NSCLC) patients survive longer than ... first-line setting, and the effect was apparent both before and ... according to research published in the June issue of the ... Asian patients with a common type of lung cancer, the ...
Cached Medicine News:Health News:Reed Elsevier Environmental Challenge winners announced 2Health News:Sex matters -- more men with migraine suffer from PTSD than women 2Health News:Sex matters -- more men with migraine suffer from PTSD than women 3Health News:Health data forum features dynamic apps, experts on June 9 2Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 2Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 3Health News:Noisy operations associated with increased infections after surgery 2Health News:Asian lung cancer patient survival exceeds Caucasians' on multiple regimens 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: